- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 342561, 11 pages
Extract of Wax Gourd Peel Prevents High-Fat Diet-Induced Hyperlipidemia in C57BL/6 Mice via the Inhibition of the PPAR Pathway
1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2College of Horticulture and Landscape Architecture, Southwest University, Chongqing 400716, China
3Key Laboratory of Horticulture Science for Southern Mountainous Regions, Ministry of Education, Chongqing 400715, China
4Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Received 30 October 2012; Accepted 26 December 2012
Academic Editor: Ken Yasukawa
Copyright © 2013 Ming Gu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Wax gourd is a popular vegetable in East Asia. In traditional Chinese medicine, wax gourd peel is used to prevent and treat metabolic diseases such as hyperlipidemia, hyperglycemia, obesity, and cardiovascular disease. However, there is no experimental evidence to support these applications. Here, we examined the effect of the extract of wax gourd peel (EWGP) on metabolic disorders in diet-induced C57BL/6 obese mice. In the preventive experiment, EWGP blocked body weight gain and lowered serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), liver TG and TC contents, and fasting blood glucose in mice fed with a high-fat diet. In the therapeutic study, we induced obesity in the mice and treated with EWGP for two weeks. We found that EWGP treatment reduced serum and liver triglyceride (TG) contents and fasting blood glucose and improved glucose tolerance in the mice. Reporter assay and gene expression analysis showed that EWGP could inhibit peroxisome proliferator-activated receptor γ (PPARγ) transactivities and could decrease mRNA levels of PPARγ and its target genes. We also found that HMG-CoA reductase (HMGCR) was downregulated in the mouse liver by EWGP. Our data suggest that EWGP lowers hyperlipidemia of C57BL/6 mice induced by high-fat diet via the inhibition of PPARγ and HMGCR signaling.
Hyperlipidemia is a serious epidemic disease involving lipid metabolism disorder and is a key pathogenic factor resulting in diabetes and cardiovascular diseases [1, 2]. The increased prevalence of hyperlipidemia has been an epidemic public and economic problem. Pharmacotherapy is the primary way of treating dyslipidemia at present, with prescription drugs, such as statins, fibrates, nicotinic acids, and bile acid sequestrants, dominating the main drug market . Although clinical trials have repeatedly proved that these drugs are effective in modulating hyperlipidemia, side effects, such as toxicity of the liver and kidneys, cannot be ignored.
Dietary therapy for dyslipidemia is an attractive way for patients to manage this condition. In China, many medicinal herbs, such as Coptis rhizome, ginseng, Astragalus mongholicus, and green tea, are used in formulas for the prevention and treatment of dyslipidemia [4–6]. Food-medicine dual plants are an important part of traditional Chinese medicine. Several food-medicine duals, such as bitter melon, ginger, celery, Citrus maxima, hawthorn, and red kojic rice, have been proven to be of benefit in dyslipidemia .
Wax gourd, also known as winter melon, white gourd, or fuzzy gourd, is the only member of the genus Benincasa, originally cultivated in Southeast Asia, and is now an important vegetable in East Asian countries. In traditional Chinese medicine, wax gourd is used as a dietary therapy for anti-inflammatory, antioxidant, and antiangiogenesis purposes and also for treating nociception, pyretic diarrhea, and ulcers [8–10]. In addition, wax gourd is used to treat obesity, hyperglycemia, hyperlipidemia, and as a protection against kidney diseases in China and other East Asian countries [11, 12]. Similarly, the seed extract of wax gourd and wax gourd peel also have ameliorate metabolic disorders, antiangiogenesis, and anticancer effects . However, little experimental data could be found to support the effects of wax gourd peel (WGP) on alleviating these metabolic disorders.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors and have been identified as drug targets for metabolic disorders. These receptors are lipid and glucose metabolism sensors and are present in adipocytes, liver, and muscle . Previous studies have shown that the inhibition of PPARγ could reduce fat and body weight and improve insulin resistance via the modulation of genes related to lipid and glucose metabolism [15–17]. Many herbal or natural medicines, that act as modulators of PPARs, have been reported to block intracellular lipid accumulation and lipogenesis and to improve insulin resistance [18, 19]. For example, Gong et al. reported that tanshinone IIA in Salvia miltiorhiza can be used to treat obesity through PPARγ antagonism . In addition, Goldwasser et al. reported that naringenin from grapefruit could regulate hepatic lipid metabolism by influencing the activity of PPARs . Huang et al. meanwhile reported that berberine from Coptis rhizome could inhibit intracellular lipid accumulation in 3T3-L1 cells by the PPARγ pathway . Here, we show that extract of wax gourd peel (EWGP) may prevent the development of hyperlipidemia and insulin resistance in high-fat diet-fed C57BL/6 mice via inhibition of the transactivities of PPARγ and reduction in the expression of its downstream genes.
2. Materials and Methods
2.1. Chemicals and Diet
WGP (Shanghai Lei Yun Shang Medicinal Materials Co.) was extracted with 75% ethanol. The extract of WGP (EWGP) was concentrated at 40°C with a rotary evaporator under reduced pressure, freezedried to a powder, and dissolved in dimethyl sulfoxide (DMSO). Rosiglitazone (Ros) and WY14643 were purchased from Sigma-Aldrich (St. Louis, MO, USA). High-fat diets (60% of calories derived from fat) and chow diet (10% of calories derived from fat) were purchased from Research Diets (D12492, D12450B).
2.2. Animals and Treatment
The animal protocols used in this study were approved by Shanghai University of Traditional Chinese Medicine. Female C57BL/6 mice were purchased from the SLAC Laboratory (Shanghai, China). All animals were kept under controlled temperature (22-23°C) and on a 12-h light, 12-h dark cycle. For the preventive treatment, the six-week-old female C57BL/6 mice were randomly divided into three groups according to body weight: chow (10% of calories derived from fat, ), high-fat (HF, 60% of calories derived from fat, ), and high-fat plus 1% EWGP (EWGP was powdered and mixed into HF diet, ). Mice were treated for 8 weeks. Twenty-four-hour food intake amount was measured by recording the difference in weight between the food put into the cage and that remaining at the end of twenty-four hours.
For the therapeutic treatment, six-week-old mice were fed with a high-fat diet for 12 weeks to induce obesity. The obese animals were then randomly separated into either the HF or EWGP group, with the latter group being treated as in the preventive treatment. The chow-control mice continued to be fed the chow diet throughout the experiment. The mice were treated in this way for 2 weeks. Body weight and food consumption were recorded every 2 days.
2.3. Intraperitoneal Glucose Tolerance Test
At the end of the treatment, mice were fasted overnight (12 h). The baseline glucose values (0 min), prior to injection of glucose (1 g/kg body weight), were measured by means of collecting blood samples from the tail vein. Additional blood samples were collected at regular intervals (15, 30, 60, and 90 min) for glucose tolerance tests.
2.4. Serum Chemistry Analysis
The mice were fasted overnight and anesthetized, and cardiac blood was taken. Serum triglyceride (TG), total cholesterol (TC), HDL cholesterol (HDL-c), and LDL cholesterol (LDL-c) were measured using a Hitachi 7020 Automatic Analyzer (Hitachi Ltd., Tokyo, Japan) using 100 μL of heart blood serum.
2.5. Determination of Intracellular Triglyceride and Cholesterol Levels
HepG2 cells were cultured in Dulbecco’s Modified Eagle Media (DMEM) containing normal glucose (5.5 mmol/L D-glucose) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 100 units/mL penicillin, and 100 μg/mL streptomycin. Cells were incubated in a humidified atmosphere of 5% CO2 at 37°C. Cells were passaged and seeded on a 12-well plate. The cell growth was quenched in serum-free DMEM, containing normal glucose, overnight when cells had grown to 70% confluence. The cells were then incubated in high glucose (30 mmol/L D-glucose) and treated with EWGP for 24 hours after serum depletion. Cells without EWGP treatment were used as a high glucose-induced lipid accumulation control. HepG2 cells were homogenized in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton), and protein concentrations in cell lysates were measured using a Bio-Rad Protein Assay Kit. Cell lysates were then mixed with an equal volume of chloroform, followed by centrifugation at 14,000 rpm for 15 min at 4°C. The chloroform layer was separated, dried, and resuspended in 50 μL of isopropyl alcohol to measure the intracellular triglyceride and total cholesterol contents as previously described . Intracellular lipid contents in HepG2 cell lysates were expressed as micrograms of lipid per milligram of cellular protein.
2.6. Liver Lipid Content Analysis
The liver tissues were weighed and homogenized in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton) and extracted with an equal volume of chloroform. The chloroform layers were dried and dissolved in isopropyl alcohol to measure lipid levels as described .
2.7. Quantitative Real-Time PCR Analysis in Animal Tissues and HepG2 Cells
The quantitative real-time PCR assay was performed as previously described . Briefly, total RNA was extracted from the liver samples using spin columns (Qiagen, Germany) according to the manufacturer’s instructions. Genomic DNA contamination was removed by using DNase I. The first strand cDNA was synthesized with a cDNA Synthesis Kit (Fermentas, Madison, WI). An ABI StepOnePlus real-time PCR system (Applied Biosystems, USA) was used to analyze the gene expression levels. The cDNA was denatured at 95°C for 10 min followed by 40 cycles of PCR (95°C, 15 s; 60°C, 60 s). The primers used in the experiments are listed in Table 1. β-actin was used as an internal control to normalize all the mRNA levels.
HepG2 cells were grown in a 12-well plate to 80% confluence with high glucose DMEM containing 10% FBS at 37°C in 10% CO2, and then EWGP was added to the medium at 200 μg/mL for 24 hours. Total RNA was extracted, and genes expression analysis was performed as described above. The primers used in the cellular experiments are listed in Table 2. β-actin was used as an internal control to normalize all the mRNA levels.
2.8. Transfection of Cultured Cells and Reporter Assays
The reporter assay was performed as previously described [20, 22]. The expression plasmid pCMXGal-mPPARα, γ-LBD, and the Gal4 reporter vector MH100 4-TK-Luc were cotransfected with a reporter construct so that 1 μg of the relevant plasmid combined with 1 μg of reporter plasmids and 0.1 μg of pREP7 (Renilla luciferase) reporter to normalize transfection efficiencies. The transfection mixture, which contained 10 μg of total plasmids and 15 μL lipofectamine 2000 (Roche) per mL of DMEM, was added to HEK293T cells for 24 h and then removed. The PPARα and PPARγ agonists (WY14643 and rosiglitazone), or EWGP, were added to fresh media and the cells were incubated for another 24 h to determine luciferase activity. We conducted the luciferase reporter assays using the Dual-Luciferase Reporter Assay System (Promega, USA), and Renilla luciferase activity was assayed to normalize transfection efficiencies. All the transfection experiments were performed in triplicate and repeated at least three times independently.
2.9. Statistical Analysis
Data analyses were performed using the statistical program SPSS 12.0 for Windows. All data were presented as means SE. Statistical analysis was performed using one-way analysis of variance (ANOVA). Differences were considered as significant (*), or not significant (NS), .
3.1. EWGP Prevents Metabolic Disorders Induced in C57Bl/6 Mice by a High-Fat Diet
To test whether EWGP blocks diet-induced body weight gain and dyslipidemia, C57BL/6 mice were fed a high-fat (HF) diet or HF diet mixed with 1% EWGP for 8 weeks. The mice fed HF diet displayed a larger body weight gain compared to the chowdiet after 8 weeks of treatment. The EWGP supplemented HF diet meanwhile blocked the body weight gain of the mice (Figure 1(a), ). The food intake amount was not significantly different between the HF and EWGP groups (Figure 1(b)), indicating that the lower body weight in EWGP-treated mice did not result from decreased calorie intake. We then assayed blood glucose and lipid levels of the mice. Figure 1(c) shows that the fasting blood glucose levels in HF-fed mice were markedly higher than that in chow-control mice, while EWGP treatment significantly lowered the fasting glucose levels in the mice (). The HF-fed mice showed higher levels of serum TC, TG, and LDL-c when compared to chow-control mice (Figure 1(d), ). EWGP-treated mice had significantly reduced serum TC and LDL-c levels compared to HF-control mice. However, TG and HDL-c levels were not significantly changed (Figure 1(d)). These results suggest that EWGP could block the body weight gain and metabolic disorders induced by a high-fat diet in C57BL/6 mice.
3.2. EWGP Improves Glucose Tolerance in Obese Mice
To study whether EWGP could alleviate metabolic disorders in obese mice, we fed mice with a HF diet (HFD) for 12 weeks to induce obesity. The obese mice were then grouped and fed with either HFD alone or HFD mixed with 1% EWGP for 2 weeks. Results showed that EWGP treatment did not significantly reduce body weight of the mice (Figure 2(a)). The food intake amount was not significantly different between the HFD and EWGP groups (Figure 2(b)). It is well known that insulin resistance commonly coexists with obesity. To understand whether EWGP improved insulin resistance in vivo, we measured the fasting blood glucose levels and glucose tolerance of the mice. The HF-fed mice exhibited higher fasting blood glucose levels when compared to chow-control mice, while the EWGP-treated group showed lower fasting glucose levels than HF-fed mice (Figure 2(c), ). We then assayed intraperitoneal glucose tolerance and found that EWGP significantly improved glucose tolerance in the obese mice at 30 and 90 min following intraperitoneal injection of glucose (Figure 2(d), ).
Next, we assayed the serum lipid levels of the mice. The HF-fed mice showed higher levels of serum TC, TG, and LDL-c when compared to those in chow-control mice (Figure 2(e), ). EWGP treatment significantly lowered serum TG levels when compared to HF-feeding (Figure 2(e), ). However, TC, HDL-c, and LDL-c levels remained unchanged. Taken together, the results indicate that EWGP could improve glucose and lipid metabolism in the obese mice.
3.3. Effect of EWGP on Lipid Accumulation in HepG2 Cells
To confirm the lipid-lowering effect of WGP, we treated human liver carcinoma HepG2 cells, a lipid metabolism cell model, with EWGP to analyze whether EWGP could ameliorate intracellular lipid metabolism. The HepG2 cells were cultured with the high-glucose medium to induce lipid accumulation, and then EWGP (200 μg/mL) was added to treat the cells for 24 hours. The results showed that EWGP notably lowered intracellular cholesterol levels (Figure 3(a), ) when compared with the vehicle control. However, we did not observe any significant effects of EWGP on intracellular triglyceride levels of HepG2 cells (Figure 3(b)), suggesting that EWGP may have an inhibitory effect on the intracellular cholesterol accumulation.
3.4. EWGP Improves Lipid Accumulation in the Liver of C57BL/6 Mice
Liver is an important organ for lipid metabolism. We measured TG and TC contents in the mouse liver of the preventive and therapeutic experiment. In the preventive treatment, TG and TC levels in the HF diet-fed mice were markedly increased when compared to those in the chow diet control mice, whereas EWGP treatment significantly decreased TG and TC accumulation in the livers of the HF diet-fed mice (Figures 4(a) and 4(b), ). In therapeutic treatment, the TG and TC levels in the obese mouse liver were markedly higher than those in the control mouse liver, while EWGP treatment significantly lowered TG contents in the obese mouse liver (Figure 4(c), ). However, TC content in EWGP-treated mouse liver was not significantly changed compared to that in obese control mice (Figure 4(d)).
3.5. EWGP Inhibits PPAR Signaling
PPARs are important regulators of lipid and glucose homeostasis through the modulation of the expression of important downstream target genes. We determined PPARα, γ transcription activities with a reporter assay system. The results showed that EWGP did not influence PPARα transcription activity (Figure 5(a)), whereas it markedly inhibited PPARγ transcription activity at concentrations of 200 μg/mL (Figure 5(b), ). To confirm this effect, we evaluated the in vivo effect of EWGP on the expression of PPARγ target genes by analyzing their mRNA expression levels in liver tissues from EWGP-treated and HF-fed control mice. The mRNA levels of PPARγ and its target genes aP2, FAS, ACC, and SCD-1 were decreased significantly, and the expression of PPARγ coactivators PGC1-α, PGC1-β was also notably lowered (Figures 5(c) and 5(d), ), whereas CD36 mRNA was not changed markedly (Figures 5(c) and 5(d)). Then, we assayed the gene expression levels of PPARα target genes, CYP4a10, and CYP4a14 . The results showed that the mRNA levels of CYP4a10 and CYP4a14 were not significantly changed in the preventive treated mouse liver (Figures 5(c) and 5(d)). However the expression of CYP4a14 was increased in the liver of therapeutic-treated mouse (Figure 5(d), ).
We then analyzed gene expression level in EWGP-treated HepG2 cells. The results showed that EWGP significantly decreased the expression level of PPARγ target genes such as aP2, CD36, and SCD-1 in HepG2 cells (Figure 5(e), ). These results indicate that EWGP could inhibit PPARγ signaling both in vivo and in vitro.
3.6. EWGP Inhibits the mRNA Level of Hmg-CoA Reductase
HMG-CoA reductase (HMGCR) is a key enzyme in cholesterol synthesis and therefore a drug target for lowering TC and TG. We found that in the liver tissues of EWGP-treated mice, the expression of HMGCR was also downregulated (Figure 5(c), ), although the expression of its upstream regulators liver X receptor α and β (LXRα, β) were not changed in EWGP-treated mouse livers (Figure 5(c)). These results indicate that wax gourd peel could inhibit the expression of HMGCR to improve metabolism disorder.
Wax gourd peel has been used as a food and in dietary medicine for prevention and treatment of lipid and glucose metabolism disorder and obesity for hundreds of years. It has been reported that four triterpenes, two sterols, a flavonoid C-glycoside, an acylated glucose, and a benzyl glycoside have been identified from Wax gourd and WGP [25, 26]. Triterpenes could lower serum cholesterol, beta-lipoproteins, and triglycerides in hyperlipidemic mice [27–29]. However, little experimental data could be obtained regarding its pharmacological mechanisms. In the present study, we provide evidence that WGP prevents metabolic disorder, and especially, ameliorates dyslipidemia in high-fat diet-fed mice. Our results not only showed that EWGP could effectively prevent lipid and glucose metabolic disorders in mice fed with a high-fat diet but also showed that EWGP had therapeutic effects in improving glucose tolerance in the obese mice.
In the preventive treatment, EWGP blocked the body weight gains in EWGP-treated mice compared with HF-fed mice. This effect is not linked to food intake as there was no notable difference in diet consumption between the groups. We also noticed differences in lipid levels between the preventive and therapeutic treatments of the mice. The TC and LDL-c levels in the preventive experiment were significantly lowered, but they were not in therapeutic experiment. This discrepancy may be a result of the shorter duration of the therapeutic treatment. In the preventive therapy, we treated mice for 8 weeks but only 2 weeks for therapeutic treatment. Extension of the therapeutic time may therefore achieve better results.
We found that EWGP inhibited the transactivity of the nuclear receptor transcription factor PPARγ but not PPARα. PPARγ is a nuclear transcription factor, expressed in a wide range of tissues including adipose tissue, liver, and intestine. PPARγ participates in mediating metabolic disorder via numerous downstream adipogenic and lipogenic genes, which are important for adipocyte maturation, lipid accumulation, and insulin-sensitive glucose transport, including FAS, ACC, aP2, SCD-1, and CD36 [15, 16, 30]. FAS and ACC are involved in triglyceride synthesis, and their expression levels are known to increase in steatotic livers of ob/ob mice . SCD-1 and CD36 are involved in fatty acid uptake and oxidation, and mice that lack SCD-1 are lean and resistant to obesity . As an adipocyte marker, aP2 modulates inflammatory responses and cholesterol ester accumulation, and deficiency in aP2 could protect against atherosclerosis and insulin resistance in the ApoE−/− mice [32–35]. PGC1-α and PGC1-β are coactivators of PPARγ signaling and have mutual promotion with PPARγ. In the liver, the PGC-1 increases lipogenesis and lipoprotein transport [36, 37]. Although PPARγ agonists such as rosiglitazone and pioglitasone improve insulin resistance and glucose tolerance in obese mice models, previous studies also have shown that inhibition of PPARγ signaling significantly improve metabolic disorders including obesity, dyslipidemia, and diabetes [20, 22]. Therefore, we postulate that effects of EWGP on metabolic disorders may be partly through the inhibition of PPARγ signaling.
Nuclear receptor transcription factor LXRs are important regulators of lipid and glucose homeostasis [38, 39]. Therefore, we also tested the gene expression levels of LXRα and β. We did not observe any alteration in the mRNA levels of LXRα and β. However, our data showed EWGP was effective in lowering TC levels in both mouse livers and HepG2 cells. HMG-CoA reductase (HMGCR) is a key enzyme in cholesterol synthesis and is the target of the lipid-lowering drug statin . Decreasing mRNA expression, or levels of the HMGCR protein, could decrease TC levels. We found that EWGP decreased HMGCR mRNA expression, suggesting that EWGP may reduce TC content through the inhibition of HMGCR. Taken together, our data indicate that EWGP may regulate lipid and glucose disorders via the inhibition of PPARγ signaling and mRNA levels of HMGCR.
In summary, our results provide evidence that EWGP played a role in ameliorating metabolic disorders in high-fat diet-fed mice. Its pharmacological mechanism may result from the suppression of PPARγ signaling and HMGCR. EWGP may be a good choice as a safe dietary strategy for preventing hyperlipidemia and other metabolic disorders. Further investigation is needed to define the mechanisms by which this component protects against metabolic disorders and whether other mechanisms exist also.
|ACC:||Acetyl coenzyme A carboxylase|
|aP2:||Adipose fatty acid-binding protein|
|CD36:||Cluster of Differentiation 36|
|Cyp4a10:||Cytochrome P450 4a10|
|Cyp4a14:||Cytochrome P450 4a14|
|FAS:||Fatty acid synthase|
|HDL-c:||High density lipoprotein cholesterol|
|IPGTT:||Intraperitoneal glucose tolerance test|
|LDL-c:||Low density lipoprotein cholesterol|
|LXR:||Liver X receptor|
|PGC1:||Peroxisome proliferator-activated receptor gamma coactivator 1|
|PPAR:||Peroxisome proliferator-activated receptor|
|WGP:||Wax gourd peel.|
Conflict of Interests
The authors report no conflict of interests.
- G. Veronica and R. R. Esther, “Aging, metabolic syndrome and the heart,” Aging and Disease, vol. 3, no. 3, pp. 269–279, 2012.
- J. G. Fodor, J. J. Frohlich, J. J. G. Genest, and P. R. M, “Recommendations for the management and treatment of dyslipidemia: report of the working group on hypercholesterolemia and other dyslipidemias,” Canadian Medical Association Journal, vol. 162, no. 10, pp. 1441–1447, 2000.
- ECE D, Pharmacy Perspectives in Dyslipidemia Management, US Pharmacist, 2010.
- S. Hasani-Ranjbar, N. Nayebi, B. Larijani, and M. Abdollahi, “A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity,” World Journal of Gastroenterology, vol. 15, no. 25, pp. 3073–3085, 2009.
- W. Jia, W. Gaoz, and L. Tang, “Antidiabetic herbal drugs officially approved in China,” Phytotherapy Research, vol. 17, no. 10, pp. 1127–1134, 2003.
- N. G. Sahib, N. Saari, A. Ismail, A. Khatib, F. Mahomoodally, and A. A. Hamid, “Plants' metabolites as potential antiobesity agents,” The Scientific World Journal, vol. 2012, Article ID 436039, 8 pages, 2012.
- M. Choudhary and K. Grover, “Development of functional food products in relation to obesity,” Functional Foods in Health and Disease, vol. 2, pp. 188–197, 2012.
- C. P. Khare, Indian Medicinal Plants: An Illustrated Dictionary, Springer, 2007.
- V. S. B Mathad, S. Chandanam, S. R. T. Setty, D. Ramaiyan, B. Veeranna, and A. B. V. Lakshminarayansettry, “Antidiarrheal evaluation of Benincasa hispida (Thunb.) Cogn. fruit extracts,” Iranian Journal of Pharmacology & Therapeutics, vol. 4, no. 1, 2005.
- V. Sabale, H. Kunjwani, and P. Sabale, “Formulation and in vitro evaluation of the topical antiageing preparation of the fruit of Benincasa hispida,” Journal of Ayurveda and Integrative Medicine, vol. 2, no. 3, p. 124, 2011.
- S. J. Lim, J. G. Jeong, M. W. Kim, S. S. Choi, H. K. Han, and J. E. Park, “Effects of Benincasa hispida intake on blood glucose and lipid level in streptozotocin induced diabetic rats,” Korean Journal of Nutrition, vol. 36, no. 4, pp. 335–343, 2003.
- K. J. Kang, S. J. Lim, J. G. Jeong et al., “Effects of wax guard on weight, triglyceride, leptin and fat cell size in rats fed on a high fat diet,” Korean Journal of Nutrition, vol. 36, no. 5, pp. 446–451, 2003.
- K. M. Sreenivas, K. Chaudhari, and S. S. Lele, “Ash gourd peel wax: extraction, characterization, and application as an edible coat for fruits,” Food Science and Biotechnology, vol. 20, no. 2, pp. 383–387, 2011.
- J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005.
- L. Guo and R. Tabrizchi, “Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance,” Pharmacology and Therapeutics, vol. 111, no. 1, pp. 145–173, 2006.
- S. E. Schadinger, N. L. R. Bucher, B. M. Schreiber, and S. R. Farmer, “PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes,” American Journal of Physiology, vol. 288, no. 6, pp. E1195–E1205, 2005.
- B. S. Muhlhausler, J. L. Morrison, and I. C. McMillen, “Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-γ target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation,” Endocrinology, vol. 150, no. 9, pp. 4287–4294, 2009.
- T. H. W. Huang, B. P. Kota, V. Razmovski, and B. D. Roufogalis, “Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome,” Basic and Clinical Pharmacology and Toxicology, vol. 96, no. 1, pp. 3–14, 2005.
- Y. Zhang, S. Fan, N. Hu et al., “Rhein reduces fat weight in db/db mouse and prevents diet-induced obesity in C57Bl/6 mouse through the inhibition of PPARγ signaling,” PPAR Research, vol. 2012, Article ID 374936, 9 pages, 2012.
- Z. Gong, C. Huang, X. Sheng et al., “The role of Tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor γ antagonism,” Endocrinology, vol. 150, no. 1, pp. 104–113, 2009.
- J. Goldwasser, P. Y. Cohen, E. Yang, P. Balaguer, M. L. Yarmush, and Y. Nahmias, “Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARα, PPARγ and LXRα,” PLoS ONE, vol. 5, no. 8, Article ID e12399, 2010.
- C. Huang, Y. Zhang, Z. Gong et al., “Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 571–578, 2006.
- M. Zang, S. Xu, K. A. Maitland-Toolan et al., “Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice,” Diabetes, vol. 55, no. 8, pp. 2180–2191, 2006.
- D. Patsouris, J. K. Reddy, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression,” Endocrinology, vol. 147, no. 3, pp. 1508–1516, 2006.
- S. Yoshizumi, T. Murakami, M. Kadoya, H. Matsuda, J. Yamahara, and M. Yoshikawa, “Medicinal foodstuffs. XI. Histamine release inhibitors from wax gourd, the fruits of Benincasa hispida COGN,” Journal of the Pharmaceutical Society of Japan, vol. 118, no. 5, pp. 188–192, 1998.
- K. Dhiman, A. Gupta, D. K. Sharma, N. S. Gill, and A. Goyal, “A review on the medicinally important plants of the family Cucurbitaceae,” Asian Journal of Clinical Nutrition, vol. 4, no. 1, pp. 16–26, 2012.
- H. Lü, J. Chen, W. L. Li et al., “Hypoglycemic and hypolipidemic effects of the total triterpene acid fraction from Folium Eriobotryae,” Journal of Ethnopharmacology, vol. 122, no. 3, pp. 486–491, 2009.
- I. K. Vasilenko, L. Lisevitskaia, L. Frolova, E. Parfent'eva, and I. Skul'te, “Hypolipidemic properties of triterpenoids,” Farmakologiia i Toksikologiia, vol. 45, no. 5, p. 66, 1982.
- H. Li, Q. J. Wang, D. N. Zhu, and Y. Yang, “Reinioside C, a triterpene saponin of Polygala aureocauda Dunn, exerts hypolipidemic effect on hyperlipidemic mice,” Phytotherapy Research, vol. 22, no. 2, pp. 159–164, 2008.
- W. Ahmed, O. Ziouzenkova, J. Brown et al., “PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?” Journal of Internal Medicine, vol. 262, no. 2, pp. 184–198, 2007.
- Y. Shi and P. Burn, “Lipid metabolic enzymes: emerging drug targets for the treatment of obesity,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 695–710, 2004.
- M. Furuhashi and G. S. Hotamisligil, “Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets,” Nature Reviews Drug Discovery, vol. 7, no. 6, pp. 489–503, 2008.
- T. Wu, J. Tian, R. G. Cutler et al., “Knockdown of FABP5 mRNA decreases cellular cholesterol levels and results in decreased apoB100 secretion and triglyceride accumulation in ARPE-19 cells,” Laboratory Investigation, vol. 90, no. 6, pp. 906–914, 2010.
- K. Maeda, K. T. Uysal, L. Makowski et al., “Role of the fatty acid binding protein mal1 in obesity and insulin resistance,” Diabetes, vol. 52, no. 2, pp. 300–307, 2003.
- L. Makowski, J. B. Boord, K. Maeda et al., “Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis,” Nature Medicine, vol. 7, no. 6, pp. 699–705, 2001.
- C. Handschin and B. M. Spiegelman, “Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism,” Endocrine Reviews, vol. 27, no. 7, pp. 728–735, 2006.
- P. Puigserver and B. M. Spiegelman, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator,” Endocrine Reviews, vol. 24, no. 1, pp. 78–90, 2003.
- N. Mitro, P. A. Mak, L. Vargas et al., “The nuclear receptor LXR is a glucose sensor,” Nature, vol. 445, no. 7124, pp. 219–223, 2007.
- P. A. Edwards, H. R. Kast, and A. M. Anisfeld, “BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis,” Journal of Lipid Research, vol. 43, no. 1, pp. 2–12, 2002.
- Y. C. Chen, Y. D. I. Chen, X. Li et al., “The HMG-CoA Reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis,” Lipids, vol. 44, no. 8, pp. 733–743, 2009.